Latest Dental Materials News

SDI Limited’s acquisition by Beijing Guoci subsidiary is now effective following New South Wales Supreme Court approval, with the ASX suspension commencing and cash payout scheduled for early July.

The Supreme Court of New South Wales has approved the scheme of arrangement for SDI Limited’s acquisition by Beijing Guoci’s subsidiary, paving the way for a cash payout and ASX suspension.

SDI Limited has satisfied key regulatory approvals and financing conditions for its proposed A$1.40 per share acquisition by a Sinocera-controlled bidder, with shareholder and court approvals still pending.

SDI Limited has dispatched its Scheme Booklet to shareholders as it moves closer to a $1.40 per share acquisition by a Beijing Guoci subsidiary. The virtual shareholder meeting is set for 22 June 2026 with strong backing from the board and largest shareholder.

SDI Limited's acquisition by Beijing Guoci's subsidiary advances with ASIC registration of the scheme booklet and court approval to convene a shareholder meeting. The all-cash offer at a 53–58% premium awaits shareholder and final court approval.

SDI Limited reported a modest 2% dip in net profit for H1 FY26 despite a 2.7% rise in sales, driven by growth in aesthetics and exports. The company faces challenges from regulatory bans on Amalgam products while advancing plans for manufacturing upgrades and a potential acquisition.

SDI Limited reported stable FY25 revenue with improved margins and advancing Montrose project, while regional sales showed mixed results.

SDI Limited reports a flat sales performance for FY25 with regional growth offset by declines in key markets, while advancing its Montrose facility project with funding plans underway.